Corporate profile
Basic information about Novartis AG
Corporate profile
Basic information about Novartis AG
Income Statement
The income statement (statement of earnings) reports on the performance of Novartis AG, the result of its operating activities.
Statement of Comprehensive Income
Comprehensive income is the change in equity (net assets) of Novartis AG during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Statement of Financial Position, Assets
The assets reports major classes and amounts of resources owned or controlled by Novartis AG.
Statement of Financial Position, Liabilities and Stockholders' Equity
The liabilities and stockholders' equity reports major classes and amounts of external claims on assets and owners' capital contributions, and other internally generated sources of capital.
Statement of Cash Flows
The cash flow statement provides information about Novartis AG's cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on Novartis AG's statement of financial position.
Common-Size Income Statement
Income statement components (revenuess and expenses) shown as percentage of total sales.
Common-Size Statement of Financial Position, Assets
Assets components shown as percentage of total assets.
Common-Size Statement of Financial Position, Liabilities and Stockholders' Equity
Liabilities and stockholders' equity components shown as percentage of total liabilities and stockholders' equity.
Short-term (Operating) Activity Analysis
Evaluates revenues and output generated by the Novartis AG's assets. Operating performance ratios describe the relationship between the Novartis AG's level of operations and the assets needed to sustain operating activities.
Long-term (Investment) Activity Analysis
Measures how efficiently Novartis AG generates revenues from its investments in fixed or total assets.
Liquidity Analysis
Measures the adequacy of a Novartis AG's cash resources to meet its near-term cash obligations.
Long-term Debt and Solvency Analysis
Examines Novartis AG's capital structure in terms of the mix of its financing sources and the ability of the firm to satisfy its longer-term debt and investment obligations.
Profitability Analysis
Measures the income of Novartis AG relative to its revenuess and invested capital.
DuPont Analysis: Decomposition of ROE
An approach to decomposing Novartis AG's return on equity as the product of other financial ratios.
Common Stock Valuation Ratios
Relative valuation technique determine the value of Novartis AG by comparing it to similar entities (like industry or sector) on the basis of several relative ratios that compare its stock price to relevant variables that affect the stock's value, such as earnings, book value, and sales.
Enterprise Value (EV)
Enterprise value is total company value (the market value of common equity, debt, and preferred equity) minus the value of cash and short-term investments.
Enterprise Value to EBITDA (EV/EBITDA)
To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital.
Enterprise Value to FCFF (EV/FCFF)
Free cash flow to the firm is the cash flow available to the Novartis AG's suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made.
Price to FCFE (P/FCFE)
Free cash flow to equity is the cash flow available to Novartis AG's equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made.
Analysis of Goodwill and Intangible Assets
Financial reporting quality relates to the accuracy with which Novartis AG's reported financial statements reflect its operating performance and to their usefulness for forecasting future cash flows.
Aggregate Accruals
Deriving measures of the accrual component of Novartis AG's earnings.
February 6, 2012